ClinicalTrials.gg
CompletedNCT07032272Updated Oct 27, 2026

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.

A Phase 1 interventional study of remibrutinib in Autoimmune and Chronic Inflammatory Diseases, sponsored by Novartis Pharmaceuticals. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Renal Insufficiency by Novartis — 1 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Novartis.

Enrollment
30th of 36
16 · median 37
Started
2025
with 1 other
Phase 1
21 of 37
1 open now
Registered
36th of 37
by date

Among the 37 studies in Renal Insufficiency by Novartis, this one is the 30th largest by enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2025, is one of 21 in phase 1, and was the 36th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

1 of the 37 studies in Renal Insufficiency by Novartis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Renal Insufficiency by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to support the development of remibrutinib dosing recommendations for patients with impaired renal function.

Read the detailed description

This is a Phase 1, open-label, non-randomized study to evaluate the PK after five administrations of remibrutinib in participants with severe RI compared to matched healthy control participants with normal renal function.The purpose of this study is to support the development of remibrutinib dosing recommendations for patients with impaired renal function.

03

Conditions studied

  • Autoimmune and Chronic Inflammatory Diseases

Browse trials for

Keywords

  • Remibrutinib (LOU064)
  • Renal impairment
  • PK
  • Safety
  • Tolerability
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

All participants (Group 1 \& 2)

  • Male and non- female participants 18 to 75 years of age, inclusive, at Screening.
  • Must be a non-smoker or a light smoker who smokes no more than 10 cigarettes (or equivalent, including use of nicotine products) per day, at Screening. Smokers must agree to smoke no more than 5 cigarettes (or equivalent) per day from check-in until after Study Completion evaluations.

Participants with severe RI (Group 1)

  • Must weigh at least 50 kg to participate in the study and must have a (BMI) within the range of 18.0 to 35.0 kg/m2, inclusive, at Screening.
  • Seated vital signs must be within the following ranges at Screening and Baseline:

    1. body temperature, 35.0 to 37.5°C, inclusive.
    2. systolic blood pressure, 90 to 159 mmHg, inclusive.
    3. diastolic blood pressure, 60 to 99 mmHg, inclusive.
    4. pulse rate, 50 to 99 bpm, inclusive.
  • Have impaired renal function as determined by using the CKD-EPI Creatinine - Cystatin C equation (2021), in the following group at Screening: severe RI; eGFR \<30 mL/min, not requiring dialysis.
  • Have stable renal function with no change in renal status prior to first dosing of study treatment as determined by the Investigator and is not currently or has not been previously on hemodialysis for at least 1 year. Participants with other stable medical disorders such as controlled diabetes, hyperlipidemia, hypothyroidism, arterial hypertension etc., may be eligible as long as they are considered appropriate for enrollment as determined by the Investigator by past medical history, physical examination, , and clinical laboratory tests at Screening.

Healthy control participants (Group 2)

  • Each healthy participant must match the age (± 10 years), body weight (± 20%), race, ethnicity and sex of an individual participant in Group 1.
  • Must weigh at least 50 kg to participate in the study and must have a BMI within the range of 18.0 to 35.0 kg/m2 inclusive, at Screening.
  • Must be in good health as determined by medical history, physical examination, ECG, vital signs and clinical laboratory tests at Screening.
  • Has normal renal function with eGFR greater than or equal to 90 mL/min, determined using the CKD-EPI Creatinine - Cystatin C equation (2021) at Screening. Actual computed over a 24-hour urine collection may be used in place of or in conjunction with the CKD-EPI Creatinine - Cystatin C equation (2021), at the Investigator's discretion.

Key Exclusion Criteria:

All participants (Group 1 \& 2)

  • Use of other drugs within 5 half-lives or 30 days prior to first dosing of study treatment, whichever is longer, as far as known.
  • History of to the study treatment or its or to drugs of similar chemical classes.
  • Use of prescription drugs, OTC medications, or herbal supplements (within the last 2 weeks prior to first dosing, or use of cannabis/marijuana, within the last 4 weeks prior to initial dosing.
  • Participants not willing to abstain from food and beverages known to inhibit or induce from 7 days prior to first dosing and until their respective EoS visit.
  • History or presence of of any organ system (other than treated localized basal cell or squamous cell carcinoma of the skin or in-situ cervical cancer), treated or untreated, within the past 5 years of Screening, regardless of whether there is evidence of local recurrence or .
  • History or presence of any ongoing, chronic or recurrent infectious disease (including tuberculosis, atypical mycobacterioses, listeriosis, aspergillosis).
  • Participants with a history of bone marrow failure or cytopenia will be excluded from the study.
  • Is on therapy or immunomodulators therapy less than or equal to 4 weeks prior to first dosing.
  • Any single parameter of (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT) or alkaline phosphatase (ALP) exceeding 1.2 x (ULN) or greater than or equal to 1.5 x ULN total (TBL) OR any elevation above ULN of more than one parameter of ALT, AST, GGT, ALP, or TBL.
  • Known or suspected diagnosis of Gilbert's syndrome.

Participants with severe RI (Group 1)

  • Clinically significant abnormal findings in physical examination, ECG, or clinical laboratory evaluations, extending over findings related to the known renal disease.
  • Participants having had myocardial infarction \< 2 years of Screening are not eligible to participate, participants having had myocardial infarction greater than or equal to 2 years of Screening can be eligible to participate.
  • Clinically significant illness within 2 weeks prior to first dosing that may jeopardize safety of the study participant and/or alter the study results as judged by the Investigator.
  • Participants with end stage renal disease requiring dialysis.

Healthy control participants (Group 2)

  • Any clinical laboratory parameters (e.g. , , leukocytes, neutrophils) outside of local laboratory ranges at Screening unless judged not clinically significant by the Investigator.
  • Significant illness which has not resolved within 2 weeks prior to first dosing of study treatment.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Participants with severe renal impairment

    Participants with severe renal impairment will receive remibrutinib

    Drug: remibrutinib

  • Experimental
    Healthy participants

    Matched healthy participants will receive remibrutinib

    Drug: remibrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax, ss of remibrutinib in blood

    The maximum (peak) observed concentration following multiple-dose administration

    Time frame: Up to 72 hours postdose

  2. AUCtau,ss of remibrutinib in blood

    The area under the curve (AUC) from time zero to the end of the dosing interval (tau) following multiple-dose administration

    Time frame: Up to 72 hours postdose

  3. Ae0-12h,ss of remibrutinib in urine

    Amount of unchanged drug excreted in the urine collection interval from time zero to 12 hours following multiple-dose administration

    Time frame: Up to 12 hours postdose

  4. CLr,ss of remibrutinib in urine

    Renal clearance following multiple-dose administration

    Time frame: Up to 12 hours postdose

Secondary outcomes

  1. Number of participants with adverse events and serious adverse events

    Number of participants with adverse events and serious adverse events

    Time frame: From Day 1 to end of study (up to 30 days after last administration of study treatment)

  2. Plasma protein binding of remibrutinib (unbound fraction)

    Fraction unbound based on protein binding data

    Time frame: 1 hour postdose

  3. Cmax,ss,u of remibrutinib in plasma

    The maximum (peak) observed unbound plasma drug concentration following multiple-dose administration

    Time frame: Up to 72 hours post dose

  4. AUCtau,ss,u of remibrutinib in plasma

    The unbound AUC calculated to the end of a dosing interval (tau) following multiple dose administration

    Time frame: Up to 72 hours post dose

  5. AUClast,ss,u of remibrutinib in plasma

    The AUC from time zero to the last measurable unbound concentration sampling time (tlast) following multiple-dose administration

    Time frame: Up to 72 hours post dose

  6. AUClast,ss of remibrutinib in blood

    The AUC from time zero to the last measurable concentration sampling time

    Time frame: Up to 72 hours postdose

  7. Tmax,ss of remibrutinib in blood

    The time to reach maximum (peak) concentration following multiple-dose administration

    Time frame: Up to 72 hours postdose

  8. T1/2 of remibrutinib in blood

    The elimination half-life associated with the terminal slope

    Time frame: Up to 72 hours postdose

  9. CL/F,ss of remibrutinib in blood

    Oral clearance following multiple-dose administration

    Time frame: Up to 72 hours postdose

07

Study locations

4 sites
  • Clinical Pharmacology of Miami LLC
    Miami, Florida 33014-3616, United States
  • Panax Clinical Research
    Miami Lakes, Florida 33014, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Genesis Clinical Research
    Tampa, Florida 33614, United States
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Oct 2025, 2 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 2 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2025
First posted
Jun 22, 2025
StartActual
Jul 23, 2025
Primary completionActual
Oct 12, 2025
CompletionActual
Oct 14, 2025
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: references
1 update, last Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Minor edits only
    + 1 other change: references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07032272
Responsible party
Sponsor
First posted
Jun 22, 2025
Start date
Jul 23, 2025
Primary completion
Oct 12, 2025
Completion
Oct 14, 2025
Last update
Oct 27, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion